VIM and breast cancer: For instance, Kusinska et al. [66] recently sought to address whether the inclusion of vimentin in an immunopanel consisting of ER, PR, HER2, and basal cytokeratins (CKs 5/6, 14 and 17) would better delineate their basal-like breast cancer definition (i.e., TNP combined with basal cytokeratin positivity) using overall survival as the primary endpoint.